CN104524100A - Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain - Google Patents
Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain Download PDFInfo
- Publication number
- CN104524100A CN104524100A CN201410754571.4A CN201410754571A CN104524100A CN 104524100 A CN104524100 A CN 104524100A CN 201410754571 A CN201410754571 A CN 201410754571A CN 104524100 A CN104524100 A CN 104524100A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicines, relates to an application of a traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain, and aims at compensating the defects in the prior art, and relieving the pain of patients with nasosinusitis. The invention provides an application of the traditional Chinese medicine composition in preparation of the medicines for treating nasosinusitis combined with facial pain. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-13 parts of scutellaria baicalensis, 4-9 parts of radix angelicae dahuricae, 5-10 parts of divaricate saposhnikovia root, 2-6 parts of wolfberry, 9-13 parts of Chinese yam, 9-13 parts of kalmegh, 2-6 parts of radix rehmanniae preparata, 2-6 parts of fructus forsythia, 9-13 parts of codonopsis pilosula, 7-11 parts of circium japonicum, 5-10 parts of agrimonia pilosa ledeb, 9-13 parts of angelica sinensis, 9-13 parts of asarum, 9-13 parts of coptis chinensis, 11-16 parts of cortex phellodendri and 8-13 parts of liquorice. The traditional Chinese medicine composition provided by the invention has significant anti-inflammatory and analgesic activities, is significant in curative effect, safe and reliable, and has a wide clinical application prospect.
Description
Technical field
The invention belongs to field of medicaments, relate to the purposes of a kind of Chinese medicine composition in preparation treatment sinusitis merging face ache medicine.
Background technology
Sinusitis is modal a kind of disease, and be nose section common disease, chronic person is in the majority.Front group of nasal sinuses is high compared with the sickness rate of posterior nasal sinuses, and wherein maxillary sinus is the most common.Nasosinustis can betide side, also can bilateral.A hole morbidity can be limited to, also can involve many holes.Face ache is the one of overall pain, is also one of modal disease.Maxillary sinus, jaw hole, sieve hole patient all can cause Head And Face pain.Sinusitis causes the reason of Head And Face pain to mainly contain: 1. the inflammatory stimulus of concha nasalis, nasal meatus, nasal sinuses mouth and sinus mucosa, the mucosa pressuring nerve tip of swelling; 2. after nasal sinuses endocrine retention accumulation, pressuring nerve tip; 3. the sinus tract of nasal sinuses, Dou Kou are due to congested, edema, and the secretions of retention is inaccessible, and GAS ABSORPTION in hole, causes low pressure or vacuum state in nasal sinuses; 4. antibacterial produces toxin and to excite nerve tip.These reasons above, not only can cause face ache, and often can reflex to head and cause headache.
The conventional treatments of sinusitis is exactly drug administration, and at present, the sinusitis Western medicine for the treatment of is a lot, but most drug therapeutic effect is poor, and treats into the shortcomings such as high, side effect is large in addition, even affects patient health time serious.In addition, also have the Chinese medicine of a lot for the treatment of sinusitis, but great majority have the shortcomings such as the low and treatment cycle of therapeutic effect difference, cure rate is long.
Summary of the invention
In order to make up the deficiencies in the prior art, alleviate the misery of sinusitis in patients, it is evident in efficacy, safe and reliable to the invention provides a kind of Chinese medicine composition for the treatment of sinusitis, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
Chinese medicine composition merges the purposes thing in face ache medicine in preparation treatment sinusitis, this Chinese medicine composition is made up of the raw material of following weight portion: Radix Scutellariae 9-13 part, Radix Angelicae Dahuricae 4-9 part, Radix Saposhnikoviae 5-10 part, Fructus Lycii 2-6 part, Rhizoma Dioscoreae 9-13 part, Herba Andrographis 9-13 part, Radix Rehmanniae Preparata 2-6 part, Fructus Forsythiae 2-6 part, Radix Codonopsis 9-13 part, Radix Cirsii Japonici 7-11 part, Herba Agrimoniae 5-10 part, Radix Angelicae Sinensis 9-13 part, Herba Asari 9-13 part, Rhizoma Coptidis 9-13 part, Cortex Phellodendri 11-16 part, Radix Glycyrrhizae 8-13 part.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.According to it, sinusitis is merged to the therapeutic effect of face ache, described Chinese medicine composition is made up of the raw material of following weight portion: Radix Scutellariae 11 parts, the Radix Angelicae Dahuricae 7 parts, Radix Saposhnikoviae 7 parts, Fructus Lycii 4 parts, Rhizoma Dioscoreae 11 parts, Herba Andrographis 11 parts, 4 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 4 parts, Radix Codonopsis 11 parts, Radix Cirsii Japonici 9 parts, Herba Agrimoniae 8 parts, Radix Angelicae Sinensis 11 parts, Herba Asari 11 parts, Rhizoma Coptidis 11 parts, Cortex Phellodendri 13 parts, 10 parts, Radix Glycyrrhizae.
In Chinese medicine composition described above, Ramulus Cinnamomi 4-9 part magnolia obovata 11-16 part can also be contained.This in two Chinese medicine can strengthen the anti-inflammatory pain-stopping effect of the above-mentioned Chinese medicine composition of the present invention further.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment sinusitis merging face ache medicine.Pharmaceutical composition of the present invention, when treating sinusitis, demonstrates remarkable anti-inflammatory and antalgic activity.Test examples 7 of the present invention shows, give positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.Test examples 8 mice of the present invention licks foot response latency time showing, compare with model group, after administration after 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control drug=hydrocortisone group also extends the incubation period that mice adds foot reaction, has certain analgesic activity, but its analgesic effect and model group there was no significant difference.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention is that inventor is through repeatedly studying, progressively improve, last successful a kind of curative effect treats the medicine of sinusitis preferably, for showing that medicine of the present invention merges the therapeutic effect of face ache to sinusitis, the present invention takes the sinusitis merging face ache of this medicine patient to 200 examples has carried out clinical observation, and selects the sinusitis with comparability to merge face ache patient 190 example as a control group.Treatment group patient takes medicine twice of the present invention every day, and sooner or later respectively once, once take 5 grams of medicines, matched group patient takes the oral drugs of conventional therapy sinusitis.Treat after one month, therapeutic outcome is in table 1.
Table 1 treatment group and treatment of control group result synopsis
| Cure | Effectively | Cure rate | Effective percentage | |
| Treatment group | 170 examples | 190 examples | 85.00％ | 95.00％ |
| Matched group | 90 examples | 110 examples | 47.37％ | 57.89％ |
Treatment group is compared matched group and is had higher cure rate and effective percentage, thinks thus, and Drug therapy sinusitis of the present invention has good effect, and through the Ureteral Calculus of month, takes medicine of the present invention and do not occur any toxic and side effects.
Chinese medicine composition of the present invention merges in tinnitus in treatment, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and existing medicine has significant synergism in anti-inflammatory and antalgic, and can significantly reduce sinusitis in patients and occur tinnitus symptom, improve acceptance and the compliance of patient.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
one) example of formulations part
embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Radix Scutellariae 10 parts, the Radix Angelicae Dahuricae 5 parts, Radix Saposhnikoviae 6 parts, Fructus Lycii 3 parts, Rhizoma Dioscoreae 10 parts, Herba Andrographis 10 parts, 3 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 3 parts, Radix Codonopsis 10 parts, Radix Cirsii Japonici 8 parts, Herba Agrimoniae 6 parts, Radix Angelicae Sinensis 10 parts, Herba Asari 10 parts, Rhizoma Coptidis 10 parts, Cortex Phellodendri 12 parts, 9 parts, Radix Glycyrrhizae.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Radix Scutellariae 12 parts, the Radix Angelicae Dahuricae 8 parts, Radix Saposhnikoviae 9 parts, Fructus Lycii 5 parts, Rhizoma Dioscoreae 12 parts, Herba Andrographis 12 parts, 5 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 5 parts, Radix Codonopsis 12 parts, Radix Cirsii Japonici 10 parts, Herba Agrimoniae 9 parts, Radix Angelicae Sinensis 12 parts, Herba Asari 12 parts, Rhizoma Coptidis 12 parts, Cortex Phellodendri 15 parts, 12 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Radix Scutellariae 11 parts, the Radix Angelicae Dahuricae 7 parts, Radix Saposhnikoviae 7 parts, Fructus Lycii 4 parts, Rhizoma Dioscoreae 11 parts, Herba Andrographis 11 parts, 4 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 4 parts, Radix Codonopsis 11 parts, Radix Cirsii Japonici 9 parts, Herba Agrimoniae 8 parts, Radix Angelicae Sinensis 11 parts, Herba Asari 11 parts, Rhizoma Coptidis 11 parts, Cortex Phellodendri 13 parts, 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Radix Scutellariae 10 parts, the Radix Angelicae Dahuricae 5 parts, Radix Saposhnikoviae 6 parts, Fructus Lycii 3 parts, Rhizoma Dioscoreae 10 parts, Herba Andrographis 10 parts, 3 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 3 parts, Radix Codonopsis 10 parts, Radix Cirsii Japonici 8 parts, Herba Agrimoniae 6 parts, Radix Angelicae Sinensis 10 parts, Herba Asari 10 parts, Rhizoma Coptidis 10 parts, Cortex Phellodendri 12 parts, 9 parts, Radix Glycyrrhizae, Ramulus Cinnamomi 5 parts, Cortex Magnoliae Officinalis 13 parts
Preparation method is with embodiment 1.
embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Radix Scutellariae 12 parts, the Radix Angelicae Dahuricae 8 parts, Radix Saposhnikoviae 9 parts, Fructus Lycii 5 parts, Rhizoma Dioscoreae 12 parts, Herba Andrographis 12 parts, 5 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 5 parts, Radix Codonopsis 12 parts, Radix Cirsii Japonici 10 parts, Herba Agrimoniae 9 parts, Radix Angelicae Sinensis 12 parts, Herba Asari 12 parts, Rhizoma Coptidis 12 parts, Cortex Phellodendri 15 parts, 12 parts, Radix Glycyrrhizae, Ramulus Cinnamomi 8 parts, Cortex Magnoliae Officinalis 12 parts.
Preparation method is with embodiment 1.
embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Radix Scutellariae 11 parts, the Radix Angelicae Dahuricae 7 parts, Radix Saposhnikoviae 7 parts, Fructus Lycii 4 parts, Rhizoma Dioscoreae 11 parts, Herba Andrographis 11 parts, 4 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 4 parts, Radix Codonopsis 11 parts, Radix Cirsii Japonici 9 parts, Herba Agrimoniae 8 parts, Radix Angelicae Sinensis 11 parts, Herba Asari 11, Rhizoma Coptidis 11 parts, Cortex Phellodendri 13 parts, 10 parts, Radix Glycyrrhizae, Ramulus Cinnamomi 6 parts, Cortex Magnoliae Officinalis 15 parts.
Preparation method is with embodiment 1.
(2) test examples part
the antiinflammatory action of embodiment 7 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, be synthetic be also naturally occurring glucocorticoid, after hydrocortisone enters cell, activate cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.
, experimental technique:
55 KM mices, male and female half and half, body weight 25-30 gram, five groups are divided at random, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls by body weight, often organize 11, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 1000mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in compositions: gavage gives 200 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition presses crude drug gauge;
Compositions low dose group: gavage gives 50 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition presses crude drug gauge;
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03 ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
, experimental result:
Measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 1.
Table 1 each experimental mice ear method of double differences compares
| Group | n | The ear method of double differences (mg) |
| Model control group | 11 | 8.44±1.20 |
| Positive controls | 11 | 6.32±1.48 * |
| Compositions high dose group | 11 | 2.86±1.78 **## |
| Dosage group in compositions | 11 | 4.52±1.52 **# |
| Compositions low dose group | 11 | 6.02±1.22 * |
Compare with model control group,
*p < 0.05; Compare with model control group,
*p < 0.01;
Compare with positive controls,
#p < 0.05; Compare with positive controls,
##p < 0.01.
Result display gives positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.
Embodiment 8 Chinese medicine composition of the present invention affects mouse hot-plate analgesic
1 mouse hot-plate pain model makes
Be placed on hot plate dolorimeter by about body weight 22g female mice, it is qualified to screen
mice 100 (licks metapedes time < 5s or > 30s to throw aside property, scald for preventing foot, also deadline should be established, be generally 60s), the incubation period of metapedes reaction is added for threshold of pain index with mice, get 60 jennies, be divided into 6 groups, 10/group, i.e. model group, cydiodine, Fructus Lycii supernatant sheet group, Chinese medicine composition of the present invention (obtaining by Chinese medicine composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 2, and after successive administration 14d, after measuring last medicine, 60min, 120min add the time of foot reaction.
2 Chinese medicine compositions of the present invention are on the impact of licking the foot response latency in mouse hot-plate analgesic experiment
Mice licks foot response latency time showing, compare with model group, after administration after 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control drug cydiodine group (
p< 0.05) and Fructus Lycii supernatant sheet group (1h,
p< 0.05; 2h,
p< 0.01) also extend the incubation period that mice adds foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.The results are shown in Table 2.
Table 2 mice lick foot response latency timetable (
±
s)
Note: compare with model group, *
p< 0.05, * *
p< 0.01
Claims (6)
1. the purposes of a Chinese medicine composition in preparation treatment sinusitis merging face ache medicine, it is characterized in that, described Chinese medicine composition is made up of the raw material of following weight portion: Radix Scutellariae 9-13 part, Radix Angelicae Dahuricae 4-9 part, Radix Saposhnikoviae 5-10 part, Fructus Lycii 2-6 part, Rhizoma Dioscoreae 9-13 part, Herba Andrographis 9-13 part, Radix Rehmanniae Preparata 2-6 part, Fructus Forsythiae 2-6 part, Radix Codonopsis 9-13 part, Radix Cirsii Japonici 7-11 part, Herba Agrimoniae 5-10 part, Radix Angelicae Sinensis 9-13 part, Herba Asari 9-13 part, Rhizoma Coptidis 9-13 part, Cortex Phellodendri 11-16 part, Radix Glycyrrhizae 8-13 part.
2. purposes as claimed in claim 1, is characterized in that, described Chinese medicine composition is also containing Ramulus Cinnamomi 4-7 part magnolia obovata 11-16 part.
3. purposes as claimed in claim 1, it is characterized in that, described Chinese medicine composition is made up of the raw material of following weight portion: Radix Scutellariae 11 parts, the Radix Angelicae Dahuricae 7 parts, Radix Saposhnikoviae 7 parts, Fructus Lycii 4 parts, Rhizoma Dioscoreae 11 parts, Herba Andrographis 11 parts, 4 parts, Radix Rehmanniae Preparata, Fructus Forsythiae 4 parts, Radix Codonopsis 11 parts, Radix Cirsii Japonici 9 parts, Herba Agrimoniae 8 parts, Radix Angelicae Sinensis 11 parts, Herba Asari 11 parts, Rhizoma Coptidis 11 parts, Cortex Phellodendri 13 parts, 10 parts, Radix Glycyrrhizae.
4. purposes as claimed in claim 4, is characterized in that, described Chinese medicine composition is also containing Ramulus Cinnamomi 4-7 part magnolia obovata 11-16 part.
5. purposes as claimed in claim 1 or 2, it is characterized in that, described Chinese medicine composition is powder, water preparation, tablet or capsule.
6. purposes as claimed in claim 1 or 2, it is characterized in that, the preparation method of described Chinese medicine composition comprises following step: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filter, filtrate recycling ethanol, cold filtration, wash with water, after drying, namely obtain Chinese medical concrete; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410754571.4A CN104524100A (en) | 2014-12-11 | 2014-12-11 | Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410754571.4A CN104524100A (en) | 2014-12-11 | 2014-12-11 | Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104524100A true CN104524100A (en) | 2015-04-22 |
Family
ID=52839856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410754571.4A Pending CN104524100A (en) | 2014-12-11 | 2014-12-11 | Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104524100A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008031095A (en) * | 2006-07-28 | 2008-02-14 | Kao Corp | Scf binding inhibitor |
| CN102274334A (en) * | 2011-09-13 | 2011-12-14 | 潞城市九鼎保健品有限公司 | Medicine for treating rhinitis and preparation method thereof |
-
2014
- 2014-12-11 CN CN201410754571.4A patent/CN104524100A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008031095A (en) * | 2006-07-28 | 2008-02-14 | Kao Corp | Scf binding inhibitor |
| CN102274334A (en) * | 2011-09-13 | 2011-12-14 | 潞城市九鼎保健品有限公司 | Medicine for treating rhinitis and preparation method thereof |
Non-Patent Citations (9)
| Title |
|---|
| 丁淑华: "《中医五官科学》", 30 June 2006, 中国中医药出版社 * |
| 中国药材公司: "《中国民间单验方》", 31 October 1994, 科学出版社 * |
| 叶建洪: "《家庭实用中草药手册.2》", 31 January 2010, 广东旅游出版社 * |
| 唐译: "《图解本草良方》", 31 January 2014, 华龄出版社 * |
| 张卓: "《疼痛名医诊治绝招大全》", 31 January 2002, 中国中医药出版社 * |
| 杜雨茂: "《中国百年百名中医临床家丛书·杜雨茂》", 31 October 2003, 中国中医药出版社 * |
| 梁斌昌: "川芎茶调散治疗急、慢性鼻窦炎20例", 《中医杂志》 * |
| 梅全喜: "《中成药临床新用》", 31 March 2001, 人民卫生出版社 * |
| 陆小左等: "《临床常见百病精治》", 30 April 2006, 天津科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103393913B (en) | Chinese medicinal composition for treating uterine prolapse | |
| CN103393966B (en) | A kind of Chinese medicine composition for the treatment of menoxenia | |
| CN102631579B (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN103356968B (en) | Traditional Chinese medicine composition for treating endometriosis | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN103599492A (en) | Medicine for treating acne | |
| CN103585545B (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN101804189A (en) | Drug for treating primary dysmenorrhea | |
| CN101732531A (en) | Medicament for treating cold | |
| CN103893502A (en) | Traditional Chinese medicine for treating phlyctenular conjunctivitis | |
| CN101491612B (en) | Medicine for treating mammary hyperplasia and early breast cancer | |
| CN103845592A (en) | Traditional Chinese medicine for treating cervical lymph node tuberculosis | |
| CN102657709A (en) | A traditional Chinese medicine for treating rhinitis | |
| CN104524100A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain | |
| CN104523989A (en) | Traditional Chinese medicine composition for treating nasosinusitis with facial pain and medicinal application thereof | |
| CN104324212A (en) | Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof | |
| CN101810831B (en) | Medicament for treating gynecological diseases | |
| CN101564483B (en) | Liver smoothing for treating hyperplasia of mammary glands | |
| CN104435629B (en) | A kind of recurrent oral ulceration for the treatment of merges Chinese medicine of laryngopharynx swelling and pain and uses thereof | |
| CN104623256A (en) | Traditional Chinese medicine composition for treating nasosinusitis | |
| CN102488864B (en) | Medicinal composition for treating herpes zoster | |
| CN105596690A (en) | Pharmaceutical composition for treating chronic tonsillitis | |
| CN104001102A (en) | Traditional Chinese medicine combination for treating children otitis media and medical application thereof | |
| CN102274393B (en) | Medicament for treating cold and preparation method thereof | |
| CN102631517B (en) | Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |